AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of EUR 191.90 billion. The enterprise value is 216.01 billion.

Market Cap	191.90B
Enterprise Value	216.01B

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	Aug 8, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.22%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 32.95.

PE Ratio	32.95
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.87, with an EV/FCF ratio of 25.11.

EV / Earnings	37.09
EV / Sales	4.68
EV / EBITDA	12.87
EV / EBIT	17.57
EV / FCF	25.11

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.77.

Current Ratio	0.93
Quick Ratio	0.71
Debt / Equity	0.77
Debt / EBITDA	1.69
Debt / FCF	3.30
Interest Coverage	10.12

Financial Efficiency

Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.28%.

Return on Equity (ROE)	16.66%
Return on Assets (ROA)	8.50%
Return on Capital (ROIC)	12.28%
Revenue Per Employee	510,693
Profits Per Employee	64,777
Employee Count	89,900
Asset Turnover	0.51
Inventory Turnover	1.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.45% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+3.45%
50-Day Moving Average	129.63
200-Day Moving Average	138.75
Relative Strength Index (RSI)	41.25
Average Volume (20 Days)	19,761

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of EUR 45.91 billion and earned 5.82 billion in profits. Earnings per share was 3.72.

Revenue	45.91B
Gross Profit	37.93B
Operating Income	12.26B
Pretax Income	7.10B
Net Income	5.82B
EBITDA	16.49B
EBIT	12.26B
Earnings Per Share (EPS)	3.72

Full Income Statement

Balance Sheet

The company has 4.42 billion in cash and 28.34 billion in debt, giving a net cash position of -23.92 billion.

Cash & Cash Equivalents	4.42B
Total Debt	28.34B
Net Cash	-23.92B
Net Cash Per Share	n/a
Equity (Book Value)	36.59B
Book Value Per Share	23.55
Working Capital	-1.59B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.16 billion and capital expenditures -1.56 billion, giving a free cash flow of 8.60 billion.

Operating Cash Flow	10.16B
Capital Expenditures	-1.56B
Free Cash Flow	8.60B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.61%, with operating and profit margins of 26.70% and 12.68%.

Gross Margin	82.61%
Operating Margin	26.70%
Pretax Margin	15.47%
Profit Margin	12.68%
EBITDA Margin	35.92%
EBIT Margin	26.70%
FCF Margin	18.73%

Dividends & Yields

This stock pays an annual dividend of 2.72, which amounts to a dividend yield of 2.19%.

Dividend Per Share	2.72
Dividend Yield	2.19%
Dividend Growth (YoY)	1.69%
Years of Dividend Growth	2
Payout Ratio	71.25%
Buyback Yield	-0.22%
Shareholder Yield	1.96%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.02.

Altman Z-Score	3.02
Piotroski F-Score	n/a